09:44 AM EST - Oncolytics Biotech Inc. : Provided an update on its partner, Adlai Nortye's, clinical progress and approval by the National Medical Products Administration (NMPA) of China for initiating a phase 3 clinical trial for pelareorep. "We congratulate Adlai on this significant regulatory and business achievement that paves the way for pelareorep's development in the world's second largest pharmaceutical market," said Andrew de Guttadauro, President of Oncolytics Biotech U.S. and Global Head of Business Development. "Since the consummation of this partnership almost two years ago, we've been very happy with how Adlai is progressing the development of pelareorep in China, the second largest and rapidly growing pharmaceutical market in the world." Oncolytics Biotech Inc.
shares T.ONC are trading unchanged at $1.16.
